Follow-up of infants given measles vaccine at 6 months of age: antibody and CMI responses to MMRII at 15 months of age and antibody levels at 27 months of age

Vaccine. 2005 May 9;23(25):3247-55. doi: 10.1016/j.vaccine.2005.01.092.

Abstract

The worldwide elimination of measles is an important target. In developed countries, to control measles outbreaks, immunization from 6 months of age is recommended. In this study, infants (n = 290) who were (1) born to mothers with natural immunity or to vaccinated mothers and (2) previously immunized with Connaught (CLL) or AIK-C measles vaccine at 6 months of age, were evaluated for measles immunity before and after measles-mumps-rubella (MMRII at 15 months of age. Eight weeks after MMRII, 98.9% of infants were seropositive by enzyme immunoassay (EIA) and 70% demonstrated measles specific cellular immunity by blast transformation (BT) of lymphocytes. At 27 months of age, 98.4% of infants had protective antibody levels by plaque reduction neutralization (PRN) test. These results suggest that AIK-C and CLL vaccines elicit durable protective immunity in young infants when used in early immunization programs.

Publication types

  • Clinical Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aging / immunology
  • Antibodies, Viral / analysis
  • Antibodies, Viral / biosynthesis*
  • Child, Preschool
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Follow-Up Studies
  • Humans
  • Immunity, Cellular / immunology
  • Immunization Schedule
  • Immunoenzyme Techniques
  • Infant
  • Lymphocyte Activation
  • Male
  • Measles Vaccine / adverse effects
  • Measles Vaccine / immunology*
  • Measles-Mumps-Rubella Vaccine / adverse effects
  • Measles-Mumps-Rubella Vaccine / immunology*
  • Neutralization Tests

Substances

  • Antibodies, Viral
  • Measles Vaccine
  • Measles-Mumps-Rubella Vaccine